Munich Center for NeuroSciences - Brain and Mind
print
Search
Hinweise zur Datenübertragung bei der Google™ Suche
Links and Functions
Breadcrumb Navigation
Content
Günter Höglinger

Prof. Dr. Günter Höglinger

GSN full member, MCN regular member

Responsibilities

Director

Contact

Klinikum der Ludwig-Maximilians-Universität München
Neurologische Klinik und Poliklinik


Website: http://www.lmu-klinikum.de/neurologie

Further Information

Keywords: Clinical Neurology, Neurodegeneration, Parkinson, Synuclein, Tau

Research methods: Therapeutic trials, clinical cohorts, biomarker discovery, neuroimaging, genetics / epigenetics, cellular neuroscience

Brief research description: The focus of my scientific work is the tight connection of patient-related research with basic research, with the aim ot develop new diagnostic and therapeutic concepts. We use both information from clinical research to develop and improve disease models (bedside to bench), and new concepts from preclinical research to be validated in human patients (bench to bedside). We concentrate our research on diseases defined by pathological propagation and aggregation of the alpha-synuclein (e.g. Parkinson’s disease, Lewy body dementia, multisystem atrophy) and the tau protein (e.g. forms of frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration). Both alpha-synuclein and tau are considered as proteinaceous infectious particles (prions), which chronically and progressively infect brain cells. Susceptibility and resilience factors are a focus of our research to develop novel therapies.

Selected publications: 

Franzmeier N, …, Höglinger G*, Ewers M*. Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications 2022;13:1362.

Höglinger GU, … Florian H. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurology 2021;20:182-192.

Dam T, … Höglinger GU, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nature Medicine 2021;27:1451-1457.

Kovacs GG, … Höglinger GU, Distribution patterns and sequential stages of tau pathology in progressive supranuclear palsy. Acta Neuropathologica 2020;140:99-119.

Höglinger GU, … Schellenberg JD. Identification of common variants influencing risk of the tauopathy Progressive Supranuclear Palsy. Nature Genetics 2011;43:699-705